TY - JOUR
T1 - Uridine-5′-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct
AU - Yitzhaki, Smadar
AU - Shainberg, Asher
AU - Cheporko, Yelena
AU - Vidne, Bernardo A.
AU - Sagie, Alex
AU - Jacobson, Kenneth A.
AU - Hochhauser, Edith
N1 - Funding Information:
Grants: This research was partially supported by the Horowitz Foundation at Bar-Ilan University and the Israel Ministry of Health No. 5904. KAJ acknowledges support from the Intramural Research Program of the NIH, National Institute of Diabetes and Digestive and Kidney Diseases. We are indebted to Ms. Sharon Victor for helping to prepare this manuscript.
PY - 2006/10/16
Y1 - 2006/10/16
N2 - We have previously found that uridine 5′-triphosphate (UTP) significantly reduced cardiomyocyte death induced by hypoxia via activating P2Y2 receptors. To explore the effect of UTP following myocardial infarction (MI) in vivo we studied four groups: sham with or without LAD ligation, injected with UTP (0.44 μg/kg i.v.) 30 min before MI, and UTP injection (4.4 μg/kg i.v.) 24 h prior to MI. Left ventricular end diastolic area (LVEDA), end systolic area (LVESA) fractional shortening (FS), and changes in posterior wall (PW) thickness were performed by echocardiography before and 24 h after MI. In addition, we measured different biochemical markers of damage and infarct size using Evans blue and TTC staining. The increase in LVEDA and LVESA of the treated animals was significantly smaller when compared to the MI rats (p < 0.01). Concomitantly, FS was higher in groups pretreated with UTP 30 min or 24 h (56 ± 14.3 and 36.7 ± 8.2%, p < 0.01, respectively). Ratio of infarct size to area at risk was smaller in the UTP pretreated hearts than MI rats (22.9 ± 6.6, 23.1 ± 9.1%, versus 45.4 ± 7.6%, respectively, p < 0.001). Troponin T and ATP measurements, demonstrated reduced myocardial damage. Using Rhod-2-AM loaded cardiomyocytes, we found that UTP reduced mitochondrial calcium levels following hypoxia. In conclusion, early or late UTP preconditioning is effective, demonstrating reduced infarct size and superior myocardial function. The resulting cardioprotection following UTP treatment post ischemia demonstrates a reduction in mitochondrial calcium overload, which can explain the beneficial effect of UTP.
AB - We have previously found that uridine 5′-triphosphate (UTP) significantly reduced cardiomyocyte death induced by hypoxia via activating P2Y2 receptors. To explore the effect of UTP following myocardial infarction (MI) in vivo we studied four groups: sham with or without LAD ligation, injected with UTP (0.44 μg/kg i.v.) 30 min before MI, and UTP injection (4.4 μg/kg i.v.) 24 h prior to MI. Left ventricular end diastolic area (LVEDA), end systolic area (LVESA) fractional shortening (FS), and changes in posterior wall (PW) thickness were performed by echocardiography before and 24 h after MI. In addition, we measured different biochemical markers of damage and infarct size using Evans blue and TTC staining. The increase in LVEDA and LVESA of the treated animals was significantly smaller when compared to the MI rats (p < 0.01). Concomitantly, FS was higher in groups pretreated with UTP 30 min or 24 h (56 ± 14.3 and 36.7 ± 8.2%, p < 0.01, respectively). Ratio of infarct size to area at risk was smaller in the UTP pretreated hearts than MI rats (22.9 ± 6.6, 23.1 ± 9.1%, versus 45.4 ± 7.6%, respectively, p < 0.001). Troponin T and ATP measurements, demonstrated reduced myocardial damage. Using Rhod-2-AM loaded cardiomyocytes, we found that UTP reduced mitochondrial calcium levels following hypoxia. In conclusion, early or late UTP preconditioning is effective, demonstrating reduced infarct size and superior myocardial function. The resulting cardioprotection following UTP treatment post ischemia demonstrates a reduction in mitochondrial calcium overload, which can explain the beneficial effect of UTP.
KW - Heart protection
KW - Ischemia
KW - P2Y receptors
UR - http://www.scopus.com/inward/record.url?scp=33748715228&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2006.07.019
DO - 10.1016/j.bcp.2006.07.019
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:33748715228
SN - 0006-2952
VL - 72
SP - 949
EP - 955
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 8
ER -